A federal jury in Boston awarded Teva Pharmaceuticals International GmbH $176.5 million in damages in a patient infringement suit against Eli Lilly and Co. for its migraine medication, Emgality.
Following a trial in the U.S. District Court for the District of Massachusetts, a jury concluded Wednesday that Lilly’s rival medication infringed on three of Teva’s patents covering its migraine medication, Ajovy. Both Emgality and Ajovy work by releasing antibodies capable of treating headache disorders associated with calcitonin gene-related peptide (CGRP).
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]